Denise Mueller

Denise Mueller is the current head of commercial strategy and business development at Affimed. Mueller has over twenty years of experience in the pharmaceutical industry, having worked at both Pfizer and Wyeth.

At Pfizer, Mueller was the asset team leader and worldwide commercial leader for two in-line musculoskeletal assets and four pipeline assets. Mueller also recommended the dissolution of the Auxilium/Pfizer collaboration and exit from the disease area, which saved Pfizer $150 million in one year. In addition, Mueller co-chaired the MSK Disease Area Leadership Team (DALT).

Mueller was also selected as the director of external opportunities, where they defined and executed the global innovative product business development strategies for the Specialty Care Business Unit. This enabled Pfizer to expand into the gene therapy business by acquiring the first gene therapy production for Pfizer. Mueller also held responsibility for the Unit’s second largest revenue generating alliance, Medtronic, which generated over $400 million in revenue at 90+% profit levels.

Lastly, Mueller was selected as the director of strategy to lead the global brand positioning and the commercial and launch strategy for Tofacitinib’s Ulcerative Colitis indication, which enabled expansion into new gastrointestinal therapeutic areas.

Denise Mueller reports to Adi Hoess, CEO. They work with Angus W. Smith - Chief Financial Officer, Arndt Schottelius - Chief Scientific Officer, and Andreas Harstrick - Chief Medical Officer.